Literature DB >> 29336016

Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors.

M de Bruin-Weller1, N M H Graham2, G Pirozzi3, B Shumel2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29336016     DOI： 10.1111/bjd.16348

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.

Authors:  Alison D Treister; Cheryl Kraff-Cooper; Peter A Lio
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

2.  Conjunctivitis in dupilumab clinical trials.

Authors:  B Akinlade; E Guttman-Yassky; M de Bruin-Weller; E L Simpson; A Blauvelt; M J Cork; E Prens; P Asbell; E Akpek; J Corren; C Bachert; I Hirano; J Weyne; A Korotzer; Z Chen; T Hultsch; X Zhu; J D Davis; L Mannent; J D Hamilton; A Teper; H Staudinger; E Rizova; G Pirozzi; N M H Graham; B Shumel; M Ardeleanu; A Wollenberg
Journal:  Br J Dermatol       Date:  2019-05-07       Impact factor: 9.302

Review 3.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

4.  Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase.

Authors:  Sunny Park; Jung Hyun Lee; Ji Hyun Park; So Hyang Park; Song Yi Park; Yong Woo Jung; Soo An Choi
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

5.  Dupilumab-Associated Mucin Deficiency (DAMD).

Authors:  Brad P Barnett; Natalie A Afshari
Journal:  Transl Vis Sci Technol       Date:  2020-02-25       Impact factor: 3.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.